Labcorp Expands FDA‑Cleared Elecsys pTau‑181 Alzheimer’s Blood Test into Primary Care
- Labcorp is rolling out Roche’s Elecsys pTau‑181 blood test nationwide in primary care for symptomatic patients aged 55+.
- Labcorp performs the test via a simple office blood draw or at more than 2,200 patient service centers.
- Labcorp aims to reduce unnecessary specialist referrals by expanding primary‑care access to Elecsys pTau‑181 for earlier diagnostic clarity.
Labcorp expands Alzheimer’s blood testing into primary care
Laboratory Corporation of America Holdings (Labcorp) is rolling out the Elecsys pTau‑181 blood test nationwide in primary care, expanding access to an FDA‑cleared biomarker for symptomatic patients aged 55 and older. Developed by Roche Diagnostics and cleared by the U.S. Food and Drug Administration in 2025, the test is performed by a simple blood draw in a physician’s office or at any of Labcorp’s more than 2,200 patient service centers. Labcorp says the move offers a more accessible alternative to brain scans or lumbar punctures for initial assessment of Alzheimer’s disease.
Labcorp positions Elecsys pTau‑181 as the first and only FDA‑cleared blood test designed to aid initial Alzheimer's evaluation in primary care, enabling clinicians to rule out Alzheimer’s pathology by identifying patients unlikely to have amyloid buildup. The company emphasizes the test’s 97.9% negative predictive value, which supports clinicians in evaluating negative cases for other causes of cognitive decline and directing positive results to further specialist testing. By expanding availability, Labcorp aims to reduce unnecessary specialist referrals and provide earlier diagnostic clarity amid a national shortage of neurologists.
The company frames the expansion as part of a broader strategy to bring blood‑based biomarkers into routine care and to support earlier, more personalized diagnosis and treatment pathways. Dr. Brian Caveney, Labcorp’s chief medical and scientific officer, says primary care clinicians are often the first point of contact for cognitive concerns and that broader access to Elecsys pTau‑181 helps patients get answers sooner and guides next steps with greater confidence. Labcorp integrates the test into its diagnostic menu and positions itself as a leader in scaling blood‑based tools that streamline care and could lower costs for patients.
Academic health leader joins board
Labcorp also appoints John H. Sampson, M.D., Ph.D., MHSc, MBA, to its board of directors effective Feb. 9, 2026. Sampson serves as vice chancellor for health affairs and dean at the University of Colorado Anschutz School of Medicine, is a practicing neurosurgeon, National Academy of Medicine member and author of nearly 300 peer‑reviewed publications; the board names him to the Quality and Compliance Committee.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

